NEW YORK (
CHANGE IN RATINGS
downgraded at JMP from Market Perform to Underperform, JMP Securities said. $26 price target. Company cut its sales outlook and has exposure to Europe.
( APKT) downgraded at Jefferies to Hold from Buy, Jefferies said. $21 price target. Hesitation by carriers to invest in wireline.
upgraded at Argus from Hold to Buy, Argus said. $74 price target. Company could be a possible takeover target.
upgraded at Baird from Underperform to Neutral, Robert Baird said. $38 price target. Company is returning cash to shareholders and shorts may soon be scrambling to cover.
upgraded to hold at TheStreet Ratings.
downgraded at Goldman to Sell, Goldman Sachs said. Company is facing increased competition and has high exposure to the defense sector. $46 price target.
downgraded at Goldman from Neutral to Sell, Goldman Sachs said. Valuation call, based on a $58 price target.
upgraded at BMO from Market Perform to Outperform, BMO Capital said. $21 price target. Solid, growing cash flow deserves a higher multiple.
rated new Hold at ThinkEquity. $84 price target. Company faces growth risks in Europe.
( CVH) downgraded at Leerink to Market Perform, Leerink Swann said. Risk/reward is less favorable, ahead of the Supreme Court decision on healthcare reform.
rated new Buy at UBS. $36 price target. Leader in non urban hospital market with a growth track record.
rated new Neutral at JP Morgan. Company still lags in several key metrics. $7 price target.
rated new Buy at UBS. $34 price target. Nation's largest healthcare provider focused on fast growing markets.
upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $39 price target. Navy demand should remain strong, relative to other areas of defense.
rated new Buy at UBS. $11 price target. Leading hospital operator in fast growing southeast non-urban market.
downgraded at Citigroup to Neutral from Buy, Citigroup said. $42.50 price target. Strong recent performance in shares.
initiated as a sell at TheStreet Ratings.
upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. Company has solid earnings quality and can grow the dividend faster than its peers. $19 price target.
downgraded at BMO to Market Perform, BMO Capital said. $40 price target. NGL pricing could remain a headwind.
downgraded at BofA/Merrill from Buy to Neutral, Bank of America/Merrill Lynch said. Valuation call, based on a $48 price target.
Universal Health Services
rated new Neutral at UBS. $43 price target. Strong behavioral segment results building on PSI acquisition.
UnitedHealth rated new Buy at Cantor Fitzgerald. $70 price target. Company is seeing above-average enrollment growth and can deliver solid earnings growth.
downgraded at Argus from Buy to Hold, Argus said. Alliance Boots purchase complicates the company's business model.
rated new Buy at Cantor. $104 price target. Company should continue to execute at peak levels.
rated new Hold at Cantor. $75 price target. Company still needs to show that enrollment and earnings can improve.
downgraded at Leerink from Outperform to Market Perform, Leerink Swann said. Valuation call; as the stock is up 8% this month, ahead of the Supreme Court ruling on healthcare reform.
STOCK COMMENTS / EPS CHANGES
numbers lowered at Credit Suisse. ADBE estimates were cut through 2014, Credit Suisse said. Company is seeing slower growth in digital marketing. Neutral rating and new $30 price target.
estimates, target raised at Morgan Stanley.Shares of DFS now seen reaching $39, according to Morgan Stanley. Estimates also increased, given better credit trends. The company may also repurchase more shares. Equal-weight rating.
Discover Financial Services numbers raised at Jefferies.Shares of DFS now seen reaching $40, Jefferies said. Estimates also raised on slower card yield compression. Buy rating.
estimates, target increased at Sterne Agee.FDX estimates were raised through 2013, Sterne Agee said. Company is cutting costs across the board. Buy rating and new $120 price target.
FedEx numbers lowered at Jefferies. Shares of FDX now seen reaching $103, Jefferies said. Estimates also lowered on lower expectations for 2013. Hold rating.
estimates, target cut at Benchmark. Shares of GOOG now seen reaching $615, according to Benchmark. Estimates also reduced, as checks show lower online advertising in Europe and domestic search volume. Hold rating.
numbers reduced at Keybanc. GRA estimates were cut through 2013, Keybanc said. Company is facing growth headwinds and is leveraged to a stronger dollar. Buy rating and new $73 price target.
numbers cut at Credit Suisse. Shares of JCP now seen reaching $25, according to Credit Suisse. Estimates also reduced, as channel checks show the company is using more markdowns.
added to Top Picks Live! at Citigroup. Passive equity stakes held by Liberty have risen significantly.
numbers cut at UBS. Shares of TAP now seen reaching $41, UBS said. Estimates also lowered on slowing share repurchases through 2013. Neutral rating.
estimates, target cut at Credit Suisse. WAG estimates were reduced through 2014, Credit Suisse said. Company may face slower growth in the U.S. Neutral rating and new $28 price target.
numbers raised at Oppenheimer. Shares of ZUMZ now seen reaching $45, Oppenheimer said. Estimates also raised on guidance bump up. Outperform rating.
>To submit a news tip, email:
READERS ALSO LIKE:
and become a fan on
This article was written by a staff member of TheStreet.